Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Gains from Sales and Divestitures (2022 - 2023)

Traws Pharma (TRAW) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $43567.0 as the latest value for Q3 2023.

  • On a quarterly basis, Gains from Sales and Divestitures rose 43.18% to $43567.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $43567.0, a 43.18% increase, with the full-year FY2022 number at $30429.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $43567.0 for Q3 2023 at Traws Pharma, roughly flat from $43567.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $43567.0 in Q1 2023 to a low of $30429.0 in Q3 2022.